Biopharmaceutical News and Research

RSS

Biopharmaceutical market generated revenues of USD 45.0 billion in 2004

New analysis from Frost & Sullivan, Strategic Analysis of the World Plant Molecular Farming Market, reveals that the biopharmaceutical market generated revenues of USD 45.0 billion in 2004. It is likely to reach USD 98.2 billion by 2011.

17 Jan 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

Genaissance patent for novel methods to correlate genetics with drug safety and efficacy

Genaissance Pharmaceuticals received a Notice of Allowance from the United States Patent and Trademark Office for a patent claiming methods for identifying correlations between the safety and efficacy of drugs and patients' unique genetic signatures.

4 Jan 2005

Manufacturers in the European active pharmaceutical ingredients market are struggling to overcome a variety of challenges

Manufacturers in the crowded and highly fragmented European active pharmaceutical ingredients (API) market are struggling to overcome a variety of challenges. One of the most pressing of these is the problem of overcapacity.

29 Nov 2004

New software for the investigation of cancer

NorayBio, a bioinformatics company located at the Bizkaia Technological Park (Basque Country) and specialising in developing software for the biosciences, has launched a new software for cancer research on to the market - BITIA, primarily aimed at research centres and cancer wards in hospitals.

16 Nov 2004

Chiron responds to FDA announcement

Chiron Corporation last Friday provided the following statement in response to an announcement by U.S. health officials on the current influenza vaccine situation.

18 Oct 2004

Flu vaccine shortage highlights need to accelerate the approval of affordable generic biopharmaceuticals and vaccines

Following the announcement that the nation is facing a flu vaccine shortage this year, the Generic Pharmaceutical Association (GPhA) renewed its call for the Food and Drug Administration (FDA) and Congress to move forward to accelerate the approval of affordable generic biopharmaceuticals and vaccines.

8 Oct 2004

University of Arizona spin-off investigates DNA damage to human skin

Niadyne, Inc., a Tucson-based spin-off biopharmaceutical company co-founded by two University of Arizona professors, has received a Small Business Innovation Research grant of nearly $750,000 to continue investigating the prevention of DNA damage to human skin

22 Sep 2004

ChemGenex discovers five new depression genes

ChemGenex Pharmaceuticals has announced that it has filed for patent protection for a further five novel depression-associated gene targets discovered by its depression and anxiety research group.

16 Sep 2004

RNAi enlisted in hunt for prawn vaccines

CSIRO researchers are using a biological phenomenon called RNA interference (RNAi) in an effort to develop a major biotechnological breakthrough for the aquaculture industry - vaccines for common prawn diseases.

16 Sep 2004

Phase I clinical trial of new drug for severe asthma

Cambridge Antibody Technology today announced that it is starting a Phase I clinical trial of CAT-354, a human anti-IL-13 monoclonal antibody, which is a potential treatment for severe asthma, following recent approval from the Medicines and Healthcare products Regulatory Agency (MHRA).

8 Sep 2004

Advances in gene silencing on the agenda

Recent advances in using 'RNA interference' (RNAi) to improve plant, animal and human health will be the major focus of the CSIRO-hosted Horizons in Livestock Sciences Conference on the Gold Coast from 12-15 September.

8 Sep 2004

MGI PHARMA acquires Aesgen for $32 million

MGI PHARMA today announced that they have signed a definitive merger agreement under which MGI PHARMA will acquire all outstanding equity of Aesgen for $32 million in cash.

1 Sep 2004

Kiwis reverse heart disease in diabetics

New Zealand biopharmaceutical company Protemix Corporation has announced the discovery of a treatment which appears to reverse heart disease in people suffering from diabetes and may lead to a more effective intervention in a major cause of death worldwide.

30 Aug 2004

Development of plant-derived topical medications to prevent HIV/AIDS and other STD's

Researchers at the Biodesign Institute at ASU have been tapped to lead development of plant-derived topical medications that would prevent HIV/AIDS and other sexually-transmitted diseases.

21 Aug 2004

IBM and Cellomics offer new solution to accelerate cell-based drug discovery

IBM and Cellomics have announced they have launched a customized information technology (IT) solution that allows biopharmaceutical scientists and academic researchers to better understand how potential drug candidates or targets of interest affect cellular function.

11 Aug 2004

Patent pending botanical extract, V38-AMF-1, completely inhibits bird flu (H5N1) and Fujian Flu

PRB Pharmaceuticals and Lee's Pharmaceuticals have announced the discovery that PRB'S patent pending botanical extract, V38-AMF-1, completely inhibits bird flu (H5N1) and Fujian Flu (H3N2) infections in vitro.

29 Jul 2004

Y's Therapeutics files for clinical trials in Europe for rheumatoid arthritis and asthma

Y's Therapeutics, a privately held biopharmaceutical company, said today it has submitted applications to the Ethics Committee and Ministry of Health (BfArM) in Germany to begin Phase II clinical trials for its two most advanced projects, YSIL6 for rheumatoid arthritis and YSTH2 for asthma.

26 Jul 2004

Emerging nanomedicine technologies could dramatically transform medical science

Emerging nanomedicine technologies could dramatically transform medical science as we know it today with their potential to address unmet medical needs and provide targeted therapy.

23 Jul 2004

Neuro3d identifies candidate compound

The identification of this compound and extension of the research collaboration by J&JPRD further highlights the strength of Neuro3d's internal drug discovery capabilities.

21 Jul 2004